In wake of bribery allegations, China pharma industry reforms urged

4 September 2013

Following the revelation of further details regarding alleged financial violations by UK pharma giant GlaxoSmithKline (LSE: GSK) and other multinationals in China (The Pharma Letter September 3), local experts have called for reforms of public hospitals and more legislation on the pharmaceutical industry, reports the China Daily.

"There are no regulations guiding how a drugmaker should promote a new product to hospitals and doctors. The doctors learned their knowledge at medical schools years ago, and they do not know about the latest developments in pharmacology," said Wang Yaoguang, director of the pharmaceutical law institute at Tsinghua University.

Mr Wang said the solution to the problem lies in the establishment of an industry regulation that guides the drug purchases of hospitals, enabling an open channel through which drug companies can pitch their products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK